Devenport J - Search Results

1

Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy.

Safy-Khan M, Jacobs JWG, de Hair MJH, Welsing PMJ, Edwardes MD, Teitsma XM, Luder Y, Devenport J, van Laar JM, Pethoe-Schramm A, Bijlsma JWJ. Safy-Khan M, et al. Among authors: devenport j. Ann Rheum Dis. 2020 Apr;79(4):460-463. doi: 10.1136/annrheumdis-2019-216537. Epub 2020 Feb 7. Ann Rheum Dis. 2020. PMID: 32033935

2

Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.

Weinblatt ME, Kremer J, Cush J, Rigby W, Teng LL, Devenport J, Singh N, Lepley D, Genovese MC. Weinblatt ME, et al. Among authors: devenport j. Arthritis Care Res (Hoboken). 2013 Mar;65(3):362-71. doi: 10.1002/acr.21847. Arthritis Care Res (Hoboken). 2013. PMID: 22972745 Free article. Clinical Trial.

3

Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment.

Keystone EC, Anisfeld A, Ogale S, Devenport JN, Curtis JR. Keystone EC, et al. J Rheumatol. 2014 Feb;41(2):216-26. doi: 10.3899/jrheum.130489. Epub 2014 Jan 15. J Rheumatol. 2014. PMID: 24429164 Free article. Clinical Trial.

4

The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy.

Conaghan PG, Peterfy C, Olech E, Kaine J, Ridley D, Dicarlo J, Friedman J, Devenport J, Troum O. Conaghan PG, et al. Among authors: devenport j. Ann Rheum Dis. 2014 May;73(5):810-6. doi: 10.1136/annrheumdis-2013-204762. Epub 2014 Feb 13. Ann Rheum Dis. 2014. PMID: 24525910 Free PMC article. Clinical Trial.

5

Relationship Between Baseline and Early Changes in C-Reactive Protein and Interleukin-6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis.

Wang J, Devenport J, Low JM, Yu D, Hitraya E. Wang J, et al. Among authors: devenport j. Arthritis Care Res (Hoboken). 2016 Jun;68(6):882-5. doi: 10.1002/acr.22765. Arthritis Care Res (Hoboken). 2016. PMID: 26473986 Free PMC article.

6

Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.

Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Devenport J, Pethö-Schramm A. Choy E, et al. Among authors: devenport j. Rheumatology (Oxford). 2019 Jun 1;58(6):1056-1064. doi: 10.1093/rheumatology/key393. Rheumatology (Oxford). 2019. PMID: 30649524 Free PMC article.

7

Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.

Bykerk VP, Östör AJK, Alvaro-Gracia J, Pavelka K, Román Ivorra JA, Nurmohamed MT, Luder Y, Sidiropoulos PNM, Devenport J, Sibilia J. Bykerk VP, et al. Among authors: devenport j. Clin Rheumatol. 2019 Sep;38(9):2411-2421. doi: 10.1007/s10067-019-04535-z. Epub 2019 Apr 26. Clin Rheumatol. 2019. PMID: 31028551

8

Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab'.

Pethoe-Schramm A, Devenport J, Reiss W. Pethoe-Schramm A, et al. Among authors: devenport j. Ann Rheum Dis. 2022 Aug;81(8):e136. doi: 10.1136/annrheumdis-2020-218365. Epub 2020 Jul 31. Ann Rheum Dis. 2022. PMID: 32737114 No abstract available.

9

Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis.

Rubbert-Roth A, Aletaha D, Devenport J, Sidiropoulos PN, Luder Y, Edwardes MD, Jacobs JWG. Rubbert-Roth A, et al. Among authors: devenport j. Rheumatology (Oxford). 2021 Feb 1;60(2):682-691. doi: 10.1093/rheumatology/keaa259. Rheumatology (Oxford). 2021. PMID: 32844216 Free PMC article.

10

Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab.

Teitsma XM, Devenport J, Jacobs JWG, Pethö-Schramm A, Borm MEA, Budde P, Bijlsma JWJ, Lafeber FPJG. Teitsma XM, et al. Among authors: devenport j. PLoS One. 2020 Dec 10;15(12):e0241189. doi: 10.1371/journal.pone.0241189. eCollection 2020. PLoS One. 2020. PMID: 33301475 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53 results

Search Page

Filters